what this node claims
AlphaFold metrics / AGRP
Model-quality receipt for the fold. It is not biological validation.
vertical proof spine
evidence / risk instrument
51%
low debt pressure
24%
70%structureusable
pLDDT 69.53
78%evidenceusable
grade B
0%gatesdebt
0/5 gates
100%riskstrong
0 hard flags
22%exportdebt
no export
33%lineagedebt
incomplete spine
proof completeness
33% missing target, candidate, finding, export- 01 target
- 02 fold
- 03 alphafold metric
- 04 candidate
- 05 finding
- 06 export
Metrics and receipt inputs
- confidence band
- low
- confidence pct
- 69.53
- coverage context
- missing or not linked
- interpretation
- weak structural context; downstream claims should be conservative
- pae context
- missing or not linked
- plddt avg
- 69.53
- sequence length
- 0
AlphaFold metrics visual
Low-confidence regions present
132 residues / min 35.16 / max 96.06 / source alphafold db
Very high
21.2%
28 residues / >=90
Confident
29.5%
39 residues / 70-89
Low
27.3%
36 residues / 50-69
Very low
22.0%
29 residues / <50
weak structural context; downstream claims should be conservative
Near-complete coverage / observed 132 of 132 residues.
- residues 16-58 / mean 47.61
- residues 75-85 / mean 60.44
- residues 123-132 / mean 61.68
- residues 1-1 / mean 65.25
proof debt register
24%
Visible limits, not hidden cleanup.
Peptide RX keeps unresolved proof debt attached to the public receipt. Some debts should be resolved; redaction and research-use boundaries should stay visible.